At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 153 enrolled
Drug / intervention
PT20 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating PT20 and Placebo for Hyperphosphataemia. Completed, enrolled 153 participants.
Detailed Summary
The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphataemia
Countries--
CollaboratorsClinipace Worldwide
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedMay 30, 2014
Enrollment StartMay 7, 2014
Primary CompletionMar 18, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.1 years ago
Interventions
PT20drug
Modified ferric oxide adipate tablets
Placebodrug
Placebo tablets matched to each PT20 dose arm